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ARTICLE
RASSF1A uncouples Wnt from Hippo signalling and
promotes YAP mediated differentiation via p73
Angelos Papaspyropoulos1, Leanne Bradley1, Asmita Thapa1, Chuen Yan Leung2,3, Konstantinos Toskas1,
Delia Koennig1, Dafni-Eleftheria Pefani1, Cinzia Raso4, Claudia Grou1, Garth Hamilton1, Nikola Vlahov1,
Anna Grawenda1, Syed Haider5, Jagat Chauhan5, Ludovico Buti6, Alexander Kanapin 7, Xin Lu6,
Francesca Buffa 5, Grigory Dianov1,8, Alex von Kriegsheim4, David Matallanas4, Anastasia Samsonova7,
Magdalena Zernicka-Goetz2,3 & Eric O’Neill 1,4
Transition from pluripotency to differentiation is a pivotal yet poorly understood develop-
mental step. Here, we show that the tumour suppressor RASSF1A is a key player driving the
early specification of cell fate. RASSF1A acts as a natural barrier to stem cell self-renewal and
iPS cell generation, by switching YAP from an integral component in the β-catenin-TCF
pluripotency network to a key factor that promotes differentiation. We demonstrate that
epigenetic regulation of the Rassf1A promoter maintains stemness by allowing a quaternary
association of YAP–TEAD and β-catenin–TCF3 complexes on the Oct4 distal enhancer.
However, during differentiation, promoter demethylation allows GATA1-mediated RASSF1A
expression which prevents YAP from contributing to the TEAD/β-catenin–TCF3 complex.
Simultaneously, we find that RASSF1A promotes a YAP–p73 transcriptional programme that
enables differentiation. Together, our findings demonstrate that RASSF1A mediates tran-
scription factor selection of YAP in stem cells, thereby acting as a functional “switch”
between pluripotency and initiation of differentiation.
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WNT, Notch, Hedgehog and Hippo signalling pathwaysplay important roles in maintaining pluripotency1.The transcriptional co-factors of the Hippo pathway,
YAP and TAZ (Wwtr1) promote stem cell self-renewal and
pluripotency by mediating TEA-domain (TEAD1-4) transcrip-
tion. Of the TEA domain family of transcription factors, TEAD2
is upregulated in embryonic stem cells (ESC)2 with TEAD2 and
TEAD4 expressed early in embryogenesis3, 4. YAP–TEAD tran-
scriptional complexes directly activate Pou5f1 (Oct4; hereafter
Oct4) expression and the subsequent expansion of pluripotent
cells5. YAP plays a crucial role in cell specification of developing
embryonic blastocysts, where in line with studies in ESCs, YAP is
also nuclear and drives pluripotency in the inner cell mass (ICM)
6. However, definition of the trophectoderm (TE) depends on
YAP-mediated expression of CDX24. This dichotomous role of
YAP in the blastocyst has been suggested to be due to tran-
scriptional cooperation with β-catenin in the ICM, but also
suggests that YAP may have distinct roles in pluripotent versus
differentiating cells, such as the TE. Accumulating evidence
supports roles for YAP and TAZ in early ESC differentiation and
terminal differentiation of tissues, guided by distinct transcription
factor selection7–10. The WNT pathway effector TCF1/LEF can
also actively repress or activate expression of Oct4, depending on
β-catenin association. In this manner, β-catenin plays a major
role as a mediator of WNT signaling in maintaining stem cell self-
renewal11, 12 but requires YAP to drive dedifferentiation of car-
diac progenitors13, indicating that WNT and Hippo converge to
regulate pluripotency.
The Hippo pathway is a signal transduction cascade where the
MST1/2 kinases activate LATS/NDR kinases to phosphorylate
YAP/TAZ. SAV1 and RASSF1-6 are direct binding scaffolds of
MST1/2 that regulate and localise pathway activation and YAP
activity. LATS/NDR-mediated phosphorylation of YAP on five
serine residues prevents association with TEADs and the
pSer127-YAP (Ser112 in mouse) site presents a binding site for
14-3-3 proteins that increases cytoplasmic retention14. During
differentiation of ESCs, activation of Hippo signalling restricts
TEAD-mediated transcription of Oct4, however, exactly how the
Hippo pathway is activated during differentiation is not known5.
While the pathways regulating pluripotency are well under-
stood, those driving early stages of transition to a differentiated
state remain elusive. The earliest specification of stem cell fate
upon exiting pluripotency has recently been reported to be
dependent on p7315, a transcriptional partner of the Hippo
pathway mediator YAP, that is also required during terminal
differentiation16–18. Activation of the Hippo pathway, resulting in
increased pSer127-YAP, is also required for optimal association
with p7319–22. Moreover, RASSF1A-mediated Hippo pathway
activation promotes both pS127-YAP and the formation of active
YAP–p73 transcriptional complexes, while loss of RASSF1A
expression allows the formation of pro-proliferative
YAP–TEAD21, 23, 24. RASSF1A silencing via promoter hyper-
methylation is widespread in solid malignancies and correlates
with a loss of pS127-YAP, elevated YAP/β−catenin mediated
transcription and increased ESC signatures in tumors25–27. Fur-
thermore, human mesenchymal stem cells harbouring targeted
promoter methylation of RASSF1A display oncogenic properties
and maintain stemness28. Thus, methylation of RASSF1A is
proposed to induce dedifferentiation of tumour cells, which may
account for poor prognosis of patients whose cancers are asso-
ciated with high levels of epigenetic silencing29, 30.
A potential role for RASSF1A in early development may be
indicated as methylation of the Rassf1A promoter is observed in
both mouse and human oocytes/zygotes and decreases as cells
pass through 2–8 cell stages of the pre-implantation embryo, in
line with increased mRNA expression31. These events occur
inversely to the methylation of Nanog and Oct4 during the epi-
genetic reprogramming of the embryo and point to a more
sophisticated regulation on the epigenome during embryogenesis.
As frequently observed for regulatory components of the pre-
implantation embryo and most recently demonstrated for
p734, 32, genetic ablation of individual Hippo components (e.g.,
Mst1, Mst2, Rassf1) in mice can demonstrate mild or late phe-
notypes due to redundancy and compensation. Importantly in
humans, epigenetic silencing of RASSF1A expression is associated
with developmental defects in the placenta, pointing to an
underappreciated role in early development33.
Here, we provide evidence that RASSF1A regulation of the
Hippo pathway effector YAP controls the balance between
pluripotency and differentiation of ESCs. We provide evidence
that YAP–TEAD2 and β-catenin–TCF3 cooperate on the Oct4
promoter to promote expression and pluripotency under stem
cell maintenance conditions. Differentiation induces expression
of RASSF1A, removing YAP from the TEAD2 complex and
disabling Oct4 transcription. We find that RASSF1A-induced
pS127-YAP is not inactive but plays an active role in differ-
entiation through direct binding to p73 and activation of lineage
specification genes.
Results
RASSF1A is expressed in differentiating stem cells. Epigenetic
regulation of genes has been widely implicated in stem cell fate
specification34. RASSF1A expression is widely observed to be
epigenetically regulated in cancer, and demethylation of the
human RASSF1A promoter has been shown to accompany dif-
ferentiation of neural progenitors into somatic cells35. To deter-
mine whether RASSF1A played a role in stem cell differentiation
we first examined levels of RASSF1A in human (H1 and H9) and
mouse (J1 and V6.5) ESC lines allowed to differentiate over a
period of 7–14 days. hRASSF1A and mRassf1A (hereafter
Rassf1A) mRNA expression increased upon differentiation of
both human and mouse ESCs (Fig. 1a, b). Using the ENCODE
Project database to compare human ESC and mesoderm-derived
progenitors, we find the RASSF1 promoter appears in a ‘poised’
epigenetic state in ESCs rather than completely silenced, as the
promoter is marked with both activating H3K4me2 and repressive
H3K27me3 histone modifications (Supplementary Fig. 1a). Dif-
ferentiation into mesoderm progenitors is coincident with loss of
the repressive mark specifically at the RASSF1 promoter CpG
island, conversion of H3K4me2 to H3K4me3 (a mark of tran-
scriptional activity) and increased transcription (Supplementary
Fig. 1a). To confirm changes in endogenous expression, a pool of
E14Tg2a mESC were allowed to terminally differentiate in the
absence of LIF (-LIF), indicated from the existence of beating
cardiac progenitor cells (Fig. 1c, Supplementary Fig. 1b and
Supplementary Movie 1). Levels of both endogenous Rassf1A
mRNA and protein were elevated in differentiated (-LIF) cells
compared to the undifferentiated (+LIF) cells (Fig. 1c). Moreover,
we find reduced CpG island promoter hypermethylation and
increased active transcription H3K4me3 chromatin marks at the
RASSF1A promoter in differentiated versus pluripotent mouse
ESCs (Fig. 1d, e and Supplementary Fig. 1a). Thus, demethylation
of Rassf1A along with elevated mRNA expression occurs when
cells move from a pluripotent state towards a more terminally
differentiated fate at the same time as expression of pluripotency
genes Nanog and Oct4 are silenced through increased DNA
methylation.
Analysis of the Rassf1A promoter for consensus binding sites
(TRANSFAC), reveals direct evidence (ChIP, ENCODE) only for
binding by the differentiation-promoting GATA family mem-
ber36, GATA1 (Fig. 1f). GATA transcription factors regulate
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Fig. 1 Epigenetic activation of Rassf1A drives ESC differentiation via GATA1. a RASSF1A and Pou5f1/Oct4 mRNA levels in undifferentiated and differentiating
human ESC lines H1 and H9. Data obtained from published GSE54186 data set. b Rassf1A mRNA levels increase upon LIF withdrawal-mediated
differentiation of mouse ESC (mESC) lines V6.5 and J1. Data obtained from published GSE3749 and GDS2672 data sets. c Rassf1A mRNA (bars) and
protein (blots) levels from undifferentiated (+LIF) versus differentiated (-LIF) E14Tg2a mESC. See also Supplementary Fig. 1b and Supplementary Movie 1. d
Rassf1A CpG island promoter methylation (assessed by qPCR for methylated/unmethylated DNA ratio) and e H3K4me3 levels in pluripotent (+LIF) versus
differentiated (-LIF) mESC. See also Supplementary Fig. 1a. f ENOCDE transcription factor ChIP data showing specific binding of GATA1 on the Rassf1A
promoter of differentiated hESC and GATA1 ChIP on the Rassf1A promoter of pluripotent (+LIF) versus differentiated (-LIF) ESC. g qPCR for Rassf1A and
Oct4 mRNA levels in response to siRNA-mediated Gata1 silencing in the presence or absence of LIF in ESC. Western blotting and qPCR indicate the level of
Gata1 KD. See also Supplementary Figs 1d–e, 2c and 5d. h Representative ESC colonies from indicated conditions subject to LIF withdrawal assay. Scale
bars: 25–50 μm. **P< 0.01 of Student’s t-test. Error bars indicate s.e.m. Data shown are representative of at least three independent experiments
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haematopoietic lineage commitment and have been increasingly
described to have roles in cell differentiation in intestinal crypts
and during early embryogenesis37, 38. We found selective binding
of GATA1 to the Rassf1A promoter and a positive association
with Rassf1A transcription in differentiating cells (Fig. 1f and
Supplementary Fig. 1c). Gata1 silencing was sufficient to
minimise Rassf1A expression in the absence of LIF, while ectopic
expression of GATA1 induced expression despite the presence of
LIF (Fig. 1g, Supplementary Fig. 1d). Furthermore, reduction of
Gata1 mRNA resulted in maintenance of Oct4 expression in the
absence of LIF, indicating that ESCs fail to differentiate in the
absence of GATA1-driven RASSF1A expression (Fig. 1g, Supple-
mentary Fig. 1d). Taken together, these data indicate that
epigenetic changes on the Rassf1A promoter are permissive for
GATA1 binding which in turn supports Rassf1A expression upon
differentiation (Supplementary Fig. 1e). Loss of either Gata1 or
Rassf1A expression resulted in ESC colonies failing to appro-
priately differentiate and persisting as pluripotent-like colonies in
the absence of LIF (Fig. 1h).
RASSF1A regulates expression of differentiation genes. To
test whether increased levels of RASSF1A plays an active role
in differentiation, we first transiently expressed RASSF1A in
mESC maintained under pluripotent conditions. RASSF1A-
positive cells were less positive for the stem cell marker
NANOG (Fig. 2a and Supplementary Fig. 2a, c, e), had reduced
number of ESC colonies and reduced expression of the plur-
ipotency gene cassette (Nanog, Oct4, Sox2) (Supplementary
Fig. 2b, d). Conversely, ESC depleted of Rassf1A, had enhanced
levels of NANOG expression which could be rescued by ectopic
expression of zsRASSF1A, but not by a derivative incapable
of activating MST kinases due to deletion of the C-terminus
(Fig. 2b and c and Supplementary Fig. 2c). Additionally, ESC
depleted of Rassf1A displaying increased Nanog, Oct4, Sox2
demonstrated a reciprocal decrease in the expression of genes
involved in lineage commitment and had increased pluripotent-
like ESC colonies (Fig. 2d and Supplementary Fig. d, f). To
determine whether ESC potency was directly regulated by
RASSF1A, we performed RNA sequencing in shRassf1A-
expressing ESC versus control (shGFP) (Fig. 2e). In the absence
of RASSF1A, genes required to maintain pluripotency and self-
renewal were upregulated, including components of the TGFβ,
WNT and Hippo pathways, SMAD2/3, LEF1 and YAP targets,
whereas factors promoting ESC differentiation, such as p53/p73
targets, Cdkn1A (p21) and Gata4, were downregulated (Fig. 2e
and Supplementary Data 1). Expression of RASSF1A is therefore
sufficient to directly regulate expression of pluripotency versus
differentiation genes.
A quaternary YAP complex induces Oct4 expression. RASSF1A
is an established component of the Hippo pathway; we therefore
set out to investigate whether its activation affects YAP–TEAD
and YAP-β-catenin transcriptional complex formation/activity,
which both have a pivotal role in maintaining stem cell self-
renewal2, 5, 13. YAP ChIP-seq demonstrated reduced association
(occupancy shift) of YAP on target genes in ESC expressing
RASSF1A compared to controls. Previously documented
YAP–TEAD/β−catenin target genes appeared more sensitive to
RASSF1A levels than classical YAP–TEAD targets which dis-
played equivalent peaks in RASSF1A-expressing ESC and con-
trols (Fig. 3a and Supplementary Fig. 3b). To assess the
transcriptional activity of YAP in response to RASSF1A expres-
sion, we combined genome-wide profiling of YAP binding
(ChIPseq) with transcriptome analysis (RNAseq) in shGFP and
shRassf1A-expressing ESC lines. There was a substantial
enrichment of YAP binding events in the immediate vicinity of
transcription start sites of genes differentially expressed following
knockdown of Rassf1A, indicating the major transcriptional
activity of YAP is negatively regulated by RASSF1A in ESC
(Supplementary Fig. 3a). As expected, TEAD was the most
upregulated transcription factor motif at sites proximal to YAP
targets in the absence of RASSF1A (Fig. 3b). Additionally, motifs
of several pluripotency-related transcription factors including
TCF7L1/2(TCF3/4), ESRRB, and SMAD2/339 (Fig. 3b and Sup-
plementary Data 2) were increased in the absence of RASSF1A.
TEAD2, TCF3/4 and β-catenin activate Oct4 transcription via
direct binding of its distal enhancer2, 40. We therefore reasoned
that RASSF1A may redirect YAP from active complexes on the
Oct4 promoter, preventing expression. Indeed, direct ChIP-qPCR
for YAP, TEAD2 and β-catenin demonstrated that in the pre-
sence of RASSF1A; YAP, TEAD2 and β-catenin have decreased
affinity for the Oct4 promoter (Fig. 3c). In keeping with our
previous results, analysis of the YAP interactome in ESCs
revealed that TEAD2, TCF3 and its co-factor β-catenin41 lose
association with YAP in response to RASSF1A expression
(Fig. 3d, Supplementary Fig. 3c and Data 3). We next examined
our separation of ESC lysates on gel filtration column and
observed co-purification of total YAP in the same fraction as β-
catenin, TCF3 and TEAD2 in the presence of LIF, however, the
co-purification is lost upon differentiation (-LIF day 4; Fig. 3e and
Supplementary Fig. 3d).
To confirm these observations, we depleted Rassf1A from
ESCs either transiently using two independent siRNA sequences
or stably, using lentiviral vectors and determined interaction by
co-immunoprecipitation. Loss of Rassf1A resulted in elevated
levels of β-catenin and TCF3 in YAP and TEAD2 immunopre-
cipitates (Fig. 3f, Supplementary Fig. 3e, f, g and 4a). The
identification of TCF3 in YAP IPs suggests the existence of a
YAP–TEAD2–β-catenin trimeric complex, which may include the
canonical β-catenin partners TCF3/4. To address this, we
employed stable shGFP, shRassf1A, shTead2 and shRassf1A/
shTead2 ESC lines transfected with siRNAs to either β-catenin,
TCF3 and TCF4, or non-targeting controls (siNT) (Supplemen-
tary Fig. 4b and c) and performed YAP ChIP using primers
identifying either TEAD or β-catenin/TCF binding sites on the
Oct4 promoter. Knockdown of shRassf1A led to an increase in
YAP occupancy of both sites on the Oct4 promoter which was
dependent on β-catenin, TCF3 and TCF4 (Fig. 3g). This implies
that β-catenin localisation to the Oct4 promoter is TEAD2-
dependent and suggests that the YAP–TEAD2–β-catenin–TCF3
complex acts as transcription-promoting unit on Oct4. In support
of this, silencing of β-catenin, TCF3 or TCF4 together with
RASSF1A (shRassf1A/siβcat; shRassf1A/siTcf7l1; shRassf1A/
siTcf7l2), reduced TEAD2 promoter binding (Fig. 3g). YAP
depletion disrupted the complex formation, confirming that
RASSF1A-mediated regulation of TEAD2-β-catenin was indeed
YAP-dependent and responsible for Oct4/Sox2/Nanog expression
and pluripotency (Supplementary Fig. 3g). Moreover, we
performed TEAD2 and β-catenin ChIP on the same target sites
of the Oct4 promoter and obtained similar results (Supplementary
Fig. 5a and b). In line with the transcriptional regulation of
Rassf1A, GATA1 overexpression also suppresses the ability of
YAP to ChIP at both binding sites in the Oct4 enhancer
(Supplementary Fig. 5c). Intriguingly, in addition to silencing of
YAP, TEAD2 or β-catenin (Supplementary Fig. 4d–f), silencing of
MST2-LATS1 in the absence of RASSF1A ablated Oct4 and Sox2
upregulation (Supplementary Fig. 5d). This suggests that the
RASSF1A signalling switch of the YAP partner not only operates
through the Hippo cassette, but may be required to facilitate
YAP-β−catenin transcription over YAP–TEAD alone as sug-
gested previously26.
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RASSF1A promotes YAP and p73 binding to differentiation
genes. LATS-dependent phosphorylation of YAP regulates its
activity in response to various signals42, 43. As shown previously,
the key LATS-dependent regulatory site, pS127-YAP, is unde-
tectable in pluripotent ESCs and increases during ESC differ-
entiation5. We also find this is the case, however, rather than
purely cytoplasmic a proportion of pS127-YAP remains nuclear
at day 5 –LIF and becomes largely nuclear by day 15 (Fig. 4a). We
also reasoned that since RASSF1A drives the formation of pro-
apoptotic YAP–p73 complexes in cancer21, 23, 24, expression of
RASSF1A may also stabilise YAP–p73 complexes in ESCs and
promote differentiation. We next examined our Gel filtration
separation of ESC d4 –LIF lysates and observed co-purification
of a small pool of total YAP marked with pS127-YAP in the
same high molecular weight fraction as p73 (Fig. 4b), indicating
the potential for complex formation. We performed a
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phosphoproteomic analysis of FLAG–YAP immunoprecipitates
from ESCs in the presence or absence of RASSF1A and, in line
with a role for the Hippo pathway, S127-YAP was phosphory-
lated when RASSF1A was expressed (Fig. 4c, Supplementary
Fig. 6a and Data 4). Moreover, in pluripotent ESCs, YAP–TEAD–
β-catenin–ΤCF3 complexes were readily detected, but were
reduced in favour of YAP–p73 in the presence of RASSF1A
(Fig. 3e, f and Supplementary Data 3). To investigate whether
YAP–p73 complexes play a role in ESC fate determination as
described for p7315, we examined genome-wide YAP DNA
binding peaks (ChIPseq). This showed that RASSF1A enriched
YAP binding to several differentiation gene promoters (e.g., p53,
Fbxw7, Klf3) containing p73 binding consensus motifs44, 45
(Supplementary Data 5). p53/p73 can promote BMP4 expression
during differentiation46 and Fbxw7 is an E3 ligase that targets c-
MYC, which is linked with development of endothelial and
hematopoietic lineages in the embryo47 and regulates GATA448.
YAP and p73 complex stabilisation by RASSF1A is dependent
on pS127. As RASSF1A signaling stabilises YAP–p73 complexes
(Fig. 4d), we speculated that the formation of these complexes
may be dependent on phosphorylation of S127. To directly
address this, ESCs were transiently transfected with either
FLAG–YAP or a non-phosphorylatable3 FLAG–YAP-S127A
mutant and complexes were retrieved by co-immunoprecipitation
of the FLAG epitope. RASSF1A expression promoted the switch
of YAP association with TEAD2 and β-catenin to p73, however,
in the context of the S127A mutant TEAD2 and β-catenin
binding was maintained (Fig. 4e). Furthermore, we performed a
proximity ligation assay (PLA), which provided evidence for close
association of pS127-YAP with p73 and, moreover, revealed that
pS127–YAP–p73 complexes could only be detected in RASSF1A-
expressing cells (Fig. 4f and Supplementary Fig. 6b). ChIP
experiments using S127A-YAP and sip73 indicated that binding
of YAP to differentiation gene promoters is pS127-YAP and p73
dependent (Fig. 4g and Supplementary Fig. 6c and d). Taken
together, these observations imply that pS127-YAP contributes to
ESC self-renewal and differentiation in response to RASSF1A
levels. In line with this, RASSF1A overexpression was accom-
panied by increased expression of 'first wave' mesoderm, endo-
derm and ectoderm-specific differentiation markers in a p73-
dependent manner15, 49 (Fig. 4h and Supplementary Fig. 6e). We
also confirmed that normal differentiating ESC require RASSF1A
expression for YAP to optimally bind to Klf3, Fbxw7 and p53
promoters and promote transcription (Supplementary Fig. 6f, g).
Finally, to ultimately test our model, ESC expressing RASSF1A or
control plasmid were induced to differentiate towards the neural
lineage by incubating in N2B27 media containing RA. RASSF1A-
expressing ESC expressed higher levels of the neuronal markers
PAX3 and SOX1, in a p73-dependent manner (Fig. 4i). This
indicates the requirement for an intact RASSF1A–YAP–p73 axis
during ESC differentiation.
RASSF1A regulates early embryonic differentiation in vivo. In
support of our model, expression profiles indicate that targeted
inactivation of OCT4 in ESCs, pushing cells out of pluripotency
towards differentiation, also increases expression of GATA1,
RASSF1A and p53/p73 targets (e.g., Mdm2, Cdkn1A, Fbxw7)
(Fig. 5a). In the early embryo, epigenetic control of totipotency is
governed by Brg1, and when Brg1 is depleted in two-cell embryos,
RASSF1A expression is increased along with associated differ-
entiation genes (Fig. 5a and Supplementary Fig 7a). As YAP
drives the early specification of cell fate in embryos, we reasoned
that RASSF1A may play a role much earlier in development than
previously anticipated. During early development the expression
pattern of Oct4 is reciprocal to Rassf1A indicating that our
observations in cultured mESCs may be directly relevant
in vivo50, 51 (Fig. 5b). Nuclear localisation of YAP during 2–8 cell
stages of the embryo (Fig. 5c), when Rassf1A expression is low, is
coincident with Oct4 transcription, which in turn triggers the
expression of additional core stem-cell markers (NANOG, SOX2)
in the ICM52. To functionally test if reciprocal expression of
OCT4 and RASSF1A regulates the switch to differentiation in the
embryo, mouse pre-implantation embryos were microinjected
with either non-targeting siRNA (siNT), siRassf1A, mRNA
encoding green florescent protein (Ctrl GFP or zsGreen) or GFP-
tagged Rassf1A mRNA (zsRassf1A) at the zygote stage and
allowed to develop to blastocysts (Supplementary Fig. 7b). Con-
sistently, at all developmental stages examined (2-cell, 4-cell, 8-
cell, 16-cell and 32-cell stage), RASSF1A loss led to maintenance
of pluripotency markers (Fig. 5d), whereas RASSF1A induction
drastically reversed the phenotype (Fig. 5e), suggesting that
RASSF1A can actively regulate the core pluripotency network in
ESCs and the mouse embryo. Embryos injected with Rassf1A
mRNA concentrations above 200 ng/μL did not develop and
concentrations higher than 300 ng/μL led to 100% lethality (0 out
of 15 embryos survived) (Fig. 5f and Supplementary Fig. 7d).
Given the positive correlations between stem cell marker deple-
tion and embryonic lethality53, we reasoned that the induced
lethality was due to premature RASSF1A-driven embryonic
differentiation. As RASSF1A appeared to exert its fate-
determining functions through p73 in ESCs, we postulated that
silencing of p73 should reverse the effects seen upon RASSF1A
induction in the mouse embryo. To test this hypothesis, we
injected embryos with 1000 ng/μL of control or Rassf1A mRNA, a
concentration which exceeded the lethality threshold, together
with siRNA to p73. Control embryos were able to form blas-
tocysts (10 out of 15), while RASSF1A-expressing embryos
arrested and died (0 out of 15 survived; Fig. 5g). Strikingly, the
lethal phenotype was rescued in embryos microinjected with both
Rassf1A mRNA and sip73, (11 out of 15 embryos survived;
Fig. 5g). Knockdown of p73 alone is not accompanied by early
developmental defects and embryos are viable at least up to
the blastocyst stage (Supplementary Fig. 7e). Together, these
data indicate that the key effector of RASSF1A signaling in
development is indeed p73.
Fig. 2 RASSF1A regulates the ESC core pluripotency network. a Representative fluorescent images of Nanog and zsRASSF1A (zsR1A)-expressing cells in
mouse ESC colonies. Bar graph and western blotting represent quantification of Nanog and RASSF1A levels, respectively. b Nanog immunofluorescence in
siNT versus siRASSF1A-transfected ESC. Additional expression of siRASSF1A-resistant zsRASSF1A rescues the phenotype in siRASSF1A-transfected ESC,
quantified in the displayed bar graphs and additionally demonstrated by Western blotting. Zoom in displays RASSF1A localisation peripherally to the
nucleus at the microtubule organising centre, in zsRASSF1A-expressing cells. Validation using a second siRNA to Rassf1A is provided in Supplementary
Fig. 2g. c qPCR for core stem cell markers from ESC in b. Ectopic expression of RASSF1A reverses the ESC pluripotent phenotype, see Supplementary
Fig 2a–e. d qPCR for germ layer-specific differentiation markers in ESC subject to LIF withdrawal. e RNAseq analysis in shRNA-expressing ESC versus
control (shGFP) reveals establishment of self-renewal and pluripotency signatures in the absence of Rassf1A, Supplementary Data 1. Scale bars: 25 and 50
μm. *P < 0.05, **P< 0.01 and ***P < 0.001, respectively, of Student’s t-test. Error bars indicate s.e.m. Data shown are representative of at least three
independent experiments
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RASSF1A represents a barrier to reprogramming in iPSC.
Rassf1A−/− mice are viable, potentially due to compensation from
the close homologue Rassf5 (49% identity) which has similar
effects in the early embryo (Supplementary Fig 7c), but tumour
prone. To determine whether tumour formation was due to a
failure to control the YAP pluripotency to differentiation switch
we isolated mouse embryonic fibroblasts (MEFs) from Rassf1A
−/− and Rassf1A+/+ littermates and subjected them to somatic cell
reprogramming as previously described54, 55 (Fig. 6a and Sup-
plementary Fig. 8a). Colony morphology, NANOG and alkaline
phosphatase staining indicated higher efficiency of iPSC genera-
tion from Rassf1A−/− MEFs than Rassf1A+/+ MEF controls
(Fig. 6b), suggesting that RASSF1A presents a barrier to repro-
gramming in agreement with results in ESCs. To confirm that the
enhanced reprogramming efficiency was due to RASSF1A, we
retrovirally introduced RASSF1A into Rassf1A−/− MEFs (Rassf1A
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−/−RASSF1A) and found that iPSC efficiency was reduced to levels
similar to Rassf1A+/+ MEFs (Fig. 6b).
We observed that in Rassf1A−/− iPSCs, endogenous mRNA
and protein levels of the core stem cell markers were elevated in
comparison to Rassf1A+/+ or Rassf1A−/−RASSF1A iPSC (Fig. 6c;
Supplementary Fig. 8c). This indicates that despite equivalent
expression of the reprogramming vector (Supplementary Fig. 8b),
iPSC colonies were restricted from commitment to pluripotency
by RASSF1A. We next wanted to confirm the regulatory switch in
transcription factor association was apparent in iPSC and found
reduced YAP association with p73 in Rassf1A−/− iPSCs compared
to control or Rassf1A−/−RASSF1A iPSC and reciprocally increased
association with TEAD2 and β-catenin (Supplementary Fig. 8d).
In agreement with our findings in ESCs, a proteomics screen in
iPSCs identified enriched association of YAP with pluripotency
associated factors in Rassf1A−/− iPSCs compared to Rassf1A+/+
or Rassf1A−/−RASSF1A iPSCs (Fig. 6d and Supplementary Data 6).
pS127-YAP levels were elevated and positively associated with
differentiation, promoting transcription factors in Rassf1A+/+ or
Rassf1A−/−RASSF1A compared to Rassf1A−/− iPSCs (Fig. 6d,
Supplementary Fig. 8e and Supplementary Data 4), thus
indicating that RASSF1A is a barrier in reprogramming to
pluripotency. Furthermore, following induction of differentiation
via LIF withdrawal, we observed the expected increases in
meso-endodermal and ectodermal markers in Rassf1A+/+ and
Rassf1A−/−RASSF1A iPSC, whereas these were lower in Rassf1A−/−
iPSC indicating a reduced capability to enter a differentiation
programme (Supplementary Fig. 8f and g). LIF withdrawal assays
demonstrated that the majority (~80%) of Rassf1A+/+ and
Rassf1A−/−RASSF1A colonies began to collapse at 4 days (80 and
95%, respectively), while 45% of Rassf1A−/− colonies sustained
their round shape (Fig. 6e and Supplementary Fig. 8h), suggesting
delayed differentiation in keeping with higher levels of core
pluripotency markers.
To assess differentiation capacity, iPSCs derived from round
colonies were challenged to form embryoid bodies (EBs) and
again differentiate towards the neural cell lineage, using defined
media containing N2B27 and RA. Neural progenitor marker
expression demonstrated that Rassf1A−/− iPSCs were less
efficient at generating neural progenitors (Fig. 6f), indicating a
requirement for RASSF1A to promote differentiation. To further
validate these results we employed a second iPSC differentiation
protocol of EBs towards the dendritic cell (DC) lineage, following
previously established methods56. FACS staining for expression
of the DC-specific cell surface marker cd54 demonstrated
that Rassf1A+/+ iPSC were more efficient at differentiating
to DCs compared to Rassf1A−/− iPSC, whereas both were
equally responsive to LPS-mediated stimulation indicating that
overall capacity to differentiate was not affected (Supplementary
Fig. 8i). Taken together, these data suggest that iPSCs
lacking RASSF1A exhibit general resistance to differentiation
signals and maintain proliferation, illustrated by insensitivity to
TGF-β-mediated inhibition and elevated Ki67 staining (Supple-
mentary Fig. 8j and k).
Discussion
The Hippo pathway is established to restrict pluripotency by
preventing YAP–TEAD-mediated activation of Oct4 transcrip-
tion52. WNT/β−catenin signalling drives maintenance of plur-
ipotency by switching the WNT effector TCF3 from a repressor
to an activator of Oct4 transcription in ESCs57. Here we
demonstrate that these two events are mutually dependant and
that both YAP–TEAD and β-catenin–TCF3 cooperate to promote
transcription of Oct4 from its distal enhancer to sustain plur-
ipotency in ESCs. Upon differentiation of ESCs, we find that the
differentiation factor GATA1 is expressed much earlier than
previously appreciated and enhances expression of the MST1/2
kinase scaffold RASSF1A37, 38. RASSF1A drives Hippo pathway
activation and pS127-YAP, which reduces YAP–TEAD interac-
tion and transcription of Oct4. Of note, MST1/2 kinases are
regulated by WW45/Sav1 in addition to RASSF1A, however
WW45/Sav1 levels were below detection in human and mouse
ESC. We find that RASSF1A-mediated Hippo activation not only
restricts YAP–TEAD binding to Oct4, but actively promotes YAP
binding to p73 to active transcriptional complexes required for
ESC differentiation. Our data suggest that a TEAD-defective
mutant of YAP may remain capable of supporting a p73-
mediated event but this remains to be tested. Moreover, we
provide evidence that the transcriptional switch is important
in vivo and responsible for the recently described role for p73 in
early lineage specification.
Alteration of DNA methylation is widely appreciated as a key
regulatory event upon fertilisation and during induction of
pluripotency in differentiated cells58. Under both processes,
erasing epigenetic memory is key in allowing transition to distinct
cellular fates. Here we find that the DNA demethylation in ESCs
and pre-implantation embryos leads to reversion of the poised
state of the Rassf1A promoter and leads to activation of Rassf1A
transcript expression towards blastocyst formation. This is a
developmentally conserved event with evidence for Rassf1A
demethylation during zebrafish, mouse and human
embryogenesis31, 59. In humans, RASSF1A expression has been
described as one of the main clinical biomarkers of placental
defects in pregnancies33, 60. Similarly, defects in p73 also associate
with risk of recurrent pregnancy loss61, and our data would
suggest that this may be linked to Hippo pathway signalling.
The Hippo pathway also plays a major role in the pre-
implantation embryo, where YAP is required for specification of
the TE and ICM4, 32. However, Yap−/− mice do not arrest until
developmental stage E8.5, implying the genetic model does not
recapitulate the early developmental role62. Despite a crucial role
in differentiation and lineage commitment, tp73−/− mice only
develop with late developmental defects due to compensation
Fig. 3 A quaternary YAP–TEAD2/β-catenin-TCF complex is essential for maintaining expression of Oct4. a YAP ChIP-seq in zsRASSF1A-overexpressing
versus control ESC depicting reduced occupancy of YAP–TEAD and YAP-β-catenin target genes in the presence of RASSF1A. See also Supplementary
Fig. 3a, b, 4 and Data 6. b Enriched sequence motifs (P< 0.05) identified in the proximity of upregulated YAP target genes upon RASSF1A loss in ESC. See
also Supplementary Data 2. c YAP, TEAD2 and β-catenin ChIP on TEAD2 and TCF binding sites (BS) on the ESC Pou5f1/Oct4 promoter in response to
indicated conditions. d Proteomics analysis for YAP binding partners in empty vector versus zsRASSF1A-transfected ESC. Factors modifying their affinity
with YAP are represented by relative abundance of peptides (LFQ intensity) and fold difference to maximum. All mass-spec intensities were normalised to
YAP intensities. See also Supplementary Fig. 3c and Data 3. e Size exclusion chromatography of ESC lysates via Gel filtration column and western blotting
with indicated antibodies. See also Supplementary Fig. 3d. f Western blotting of YAP and TEAD2 immunoprecipitates in response to transient depletion of
RASSF1A. Validation using #2 siRassf1A and shRassf1A is provided in Supplementary Fig. 3e–g. g YAP ChIP at TEAD and β-catenin/TCF binding sites (BS)
on the ESC Pou5f1/Oct4 promoter in response to stable ablation of RASSF1A versus control. *P< 0.05, **P< 0.01 and ***P< 0.001, respectively, of Student’s
t-test. Error bars indicate s.e.m. Data shown are representative of at least three independent experiments
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from p53 in the early embryo15. Similarly, individual
genetic ablation of Hippo pathway kinases Ndr1/2, Lats1/2 and
Mst1/2 only display phenotypes upon dual deletion of both
isoforms, and tumour prone Rassf1A−/− mice are viable, report-
edly due to compensation from the homologous family
member Rassf563, 64. In keeping with the widespread role as a
tumour suppressor in humans, Rassf1A−/− mice succumb to a
variety of tumours, indicating a potential weakening of a
pluripotency to differentiation switch that is not completely
compensated for in the null mice. This is supported by increased
pluripotent reprogramming efficiency of Rassf1A−/− MEFs
suggesting that RASSF1A maintains differentiation of fibroblasts
and represents a barrier to reprogramming during iPSC genera-
tion. Moreover, the loss of RASSF1A in human tumours is
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associated with lower differentiation grade and increased stem
cell characteristics.
Taken together, our findings clearly show that RASSF1A
mediates a switch of factors that YAP promotes transcription
through and that this is crucial in maintaining the balance
between pluripotency and differentiation. Thus, RASSF1A is a
key mechanism that determines transition from pluripotency to
differentiation in ESCs via WNT/Hippo pathway transcription
factor competition. As RASSF1A is an established tumour sup-
pressor, our finding of a major role in stem cell biology highlights
a significant regulatory event that may contribute to tumour-
igenesis and provides a link between tumour formation and
dedifferentiation.
Methods
Cell lines and culture. E14Tg2a mouse ESCs (obtained from ATCC), iPS cells and
the subsequently derived stable lines (shGFP, shRassf1a, shTead2, shRassf1a/
shTead2-expressing cell lines) were maintained in cell culturing medium consisting
of DMEM (High Glucose, Sodium Pyruvate, Gibco) supplemented with 0.01% LIF
(ESGRO, Millipore), 10% Knockout Serum Replacement (Invitrogen), 2% ES-grade
Foetal Calf Serum (Invitrogen), 1% L-glutamine (Gibco), 1% non-essential amino
acids (Gibco) and 0.0008% β-mercaptoethanol (Sigma). The cells were kept at
37 oC in 5% CO2 and 20% O2 and cultured in gelatin-coated dishes or flasks (0.1%
gelatin, Sigma). MEF cell lines were kindly provided by the David Adams
laboratory, Cambridge, UK and maintained in DMEM (high glucose, sodium
pyruvate, Gibco) supplemented with 10% foetal bovine serum, 1% glutamine and
1% penicillin/streptomycin at 37 oC in 5% CO2 and 3% O2. Mitomycin C (Sigma, 2
mg)-treated MEF SNL76/7 cells (obtained from ATCC) were used as the feeder
layer for somatic reprogramming as well as adjusting E14Tg2a cells in feeder-free
culture. Cells were routinely tested and found negative for mycoplasma infections.
Co-immunoprecipitation. For lysate preparation, 7 × 106 cells were lysed in ice-
cold 1% (v/v) Nonidet P40 lysis buffer (20 mM Hepes pH 7.5, 1% NP40 (Roche),
150 mM NaCl, 0.5 mM EDTA, 50 mM NaF, 10 mM β-glycerophosphate, 0.5 mM
Na3VO4 and 1 × EDTA free protease inhibitors (Roche)). Lysates were cleared by
centrifugation at 4 °C at 10,000×g for 10 min and then were subject to sonication
for 15 s at 20% amplitude. Samples were normalised with Bradford protein assay
and equal volumes of protein (1–2 mg) were used per reaction per experiment.
Immunocomplexes were precipitated with Protein G sepharose (Sigma) or Protein
G Dynabeads (Life Technologies). The antibodies used were: anti-YAP (H-125; sc-
15404), anti-YAP (clone 63.7;sc-101199), anti-TEF-4 (sc-67115). IPs were incu-
bated on an end-to-end rotator for 3 h at 4 °C and, afterwards, the beads were
washed three times with NP40 wash buffer. IP samples were resuspended in 50 μL
1 × Laemmli sample buffer (12.5% glycerol (v/v), 2% SDS (w/v), 78 mM Tris pH
6.8, 720 mM β-mercaptoethanol, bromophenol blue) and boiled (100 °C; 5 min).
Size exclusion chromatography. Whole cell extracts were prepared by resus-
pending frozen pellets in one packed-cell volume of buffer containing 10 mM Tris-
HCl (pH 7.8), 200 mM KCl, 1 mg/ml of each protease inhibitor (pepstatin, apro-
tinin, chymostatin and leupeptin) and 1 mM PMSF 1 mM NEM. Five milligrams of
protein in 200 μL were filtered through 0.45-μm cellulose acetate membrane and
loaded onto a Superdex 200 HR 10/30 column (GE Healthcare, Little Chalfont,
UK) prewashed with 2 column volumes of running buffer (20 mM HEPES pH 7.5,
150 mM NaCl, 0.5 mM EDTA, 0.25 mM DTT) and ran with the same buffer at a
flow rate of 0.5 ml/min. 0.25-ml fractions were collected and 10 microlites of each
fraction were analysed by Western blot. The column was calibrated with the fol-
lowing protein standards: thyroglobulin (669 kDa), apoferritin (443 kDa), alcohol
dehydrogenase (150 kDa), bovine serum albumin (66 kDa), carbonic anhydrase
(29 kDa), and aprotinin (6.5 kDa).
Immunoblot analysis. Input samples were lysed in Laemmli Lysis Buffer (50 mM
Tris-HCl pH 6.8, 2% SDS, 50 mM NaF, 10 mM β-glycerophosphate, 0.5 mM
Na3VO4 and 1 × EDTA free protease inhibitors (Roche)) and normalised by
NanoDrop (Thermo Scientific). Immunoprecipitates and cell lysates were western
blotted as previously described65. The following primary antibodies were used at a
concentration of 1:1000; TEF-4 (sc-67115), β-catenin (sc-7199), p73 (ep436Y),
YAP (sc-15404 and sc-101199), Gapdh (abcam;2251-1; 1/10000), Tcf-3 (sc-
166411), FLAG (M2; Agilent; 200472-21), Rassf1a (sc-58470), HA (Millipore;05-
904), Nanog (ab80892), Oct4 (ab19857), TEF-1 (BD Laboratories;610922), Tcf-4
(Cell Signaling; C48H11/2569), LATS1 (Bethyl Laboratories; A300-477A-1), pS127
YAP (Cell Signaling; 4911), pY357 YAP (ab62751), pSer (ab9332), GATA-1 (sc-
13053), MST2 (ab52641) and HRP conjugated anti-mouse and anti-rabbit sec-
ondary antibodies were used at a concentration of 1:5000 (Jackson Immunor-
esearch). Uncropped western blots of key experiments can be found in
Supplementary Figs 9–11.
Mass spectrometry. Samples were prepared according to the co-
immunoprecipitation protocol from whole cell lysates (see above) with a
few modifications. Specifically, only Protein G Dynabeads (Life Technologies)
were used to precipitate the proteins of interest. Moreover, after the 3 h
incubation on the end-to-end rotator, the immunoprecipitates were washed
four times, the two first being with NP40 lysis buffer and the last two only
with filtered PBS. Finally, the tubes were left uncapped to air-dry for approximately
15 min and no Laemmli sample buffer was added to the immunoprecipitates.
The samples were subject to mass spectrometry analysis using an Orbitrap mass
spectrometer.
Methylation-specific polymerase chain reaction (PCR). The genomic DNA
from pluripotent and differentiated mouse ESC was isolated using the Dneasy
Blood and Tissue kit (Qiagen) according to the manufacturer’s instructions. The
methylation status of the Rassf1a promoter region was determined by chemical
modification of genomic DNA with sodium bisulfite and methylation-specific PCR.
Bisulfite treatment converts cytosine bases to uracil bases but has no effect on 5-
methylcytosine bases. The bisulfite-treated DNA was used as a template for the
methylation-specific PCR reaction. Primers for the unmethylated DNA-specific
reaction were: FW: 5′-GGTGTTGAAGTTGTGGTTTG-3′ and REV: 5′-TATTA-
TACCCAAAACAATACAC-3′. Primers for the methylated DNA-specific reaction
were: FW: 5′-TTTTGCGGTTTCGTTCGTTC-3′ and REV: 5′-CCCGAAACG-
TACTACTATAAC-3′66.
qPCR analysis. Quantitative Real-Time PCR was done according to the Power
SYBR Green Cells-to-Ct kit protocol (Applied Biosystems). After the production of
cDNA, the cDNA was diluted down 2–4 times in Nuclease-free water. The PCR
Cocktail was then assembled, containing the forward and reverse primers. Reac-
tions were performed in 96-well plates (Life Technologies) and the PCR instrument
(Applied Biosystems) was programmed as follows: Stage 1. Enzyme activation
(hold), repeats 1, temperature 95 °C, time 10 min, Stage 2. PCR (cycle), repeats 40,
Step 1. Temperature 95 °C, time 15 s, Step 2. Temperature 60 °C, time 1 min, Stage
3. Dissociation curve, Step 1. Temperature 95 °C, time 15 s, Step 2.
Temperature 60 °C, time 1 min, Step 3. Temperature 95 °C, time 30 s, Step 4.
Temperature 60 °C, time 15 s. The further analysis of the results was done using the
machine software. For qRT-PCR following ChIP and ChIP seq, the Input samples
were at a concentration of 2.5 ng/μL. The following primers were used: Oct4 FW:
TGTGGACCTCAGGTTGGACT and REV: TTTCATGTCCTGGGACTCCTC,
Nanog FW: AAGGATGAAGTGCAAGCGGT and REV: GGTGCTGAGCCC
TTCTGAATC, Sox2 FW: CAGGAGTTGTCAAGGCAGAGA and REV:
CTTAAGCCTCGGGCTCCAAA, Bmp4 FW: ACCAATGGAGCCATTCCGTA
and REV: ACGACCATCAGCATTCGGTT, Vimentin FW: AGCAGTAT-
GAAAGCGTGGCT and REV: CAGGGACTCGTTAGTGCCTTT, Gata4 FW:
GCTCCATGTCCCAGACATTC and REV: ATGCATAGCCTTGTGGGGAC,
Nestin FW: GAGGCGCTGGAACAGAGATT and REV: CACAGCCAGCTG-
GAACTTTTC, Rassf1a FW: GTGGAGACTTCATCTGGGGC and REV:
Fig. 4 RASSF1A regulates LATS-mediated YAP phosphorylation and enforces differentiation entry via p73. a Subcellular localisation and expression of total
YAP and pS127-YAP in gradually differentiating ESC cultures. pS127-YAP is significantly increased upon differentiation. b Size exclusion chromatography of
ESC lysates via Gel filtration column and western blotting with indicated antibodies. c Phosphoproteomic analysis of YAP phosphorylation in RASSF1A-
expressing versus non-expressing ESC. All cells are transfected with human FLAG–YAP1. All mass-spec intensities were normalised to YAP intensities for
each sample. See also Supplementary Fig 6a and Data 4. d Western blotting of YAP immunoprecipitates under indicated conditions for the indicated
antibodies and quantification of p73 relative ratio to YAP. e Western blotting of FLAG immunoprecipitates from ESC transfected with the indicated
constructs. FLAG–YAP mutants are triple-tagged. f Proximity ligation assay (PLA) demonstrates association of anti-pS127-YAP with anti-p73 antibodies.
Red dots indicate positive association. The graph reports number of PLA events between p73/pS127 in the presence or absence of RASSF1A. See also
Supplementary Fig 6b. g YAP ChIP on indicated differentiation-related gene promoters and h qPCR for germ layer-specific differentiation markers in ESC in
response to indicated conditions. See also Supplementary Data 6. i ESC cultures expressing zsRASSF1A or empty vector (zsCtrl) were subject to neural
differentiation assay via N2B27 and retinoic acid (RA). Scale bars: 25–50 μm. *P< 0.05, **P< 0.01 and ***P< 0.001, respectively, of Student’s t-test. Error
bars indicate s.e.m. Data shown are representative of at least three independent experiments
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CAGCCTCATCCACGTTCGTA, Gapdh FW: CTCCACTCACGGCAAATTCA
and REV: CGCTCCTGGAAGATGGTGAT, Sox1 FW: CTGCAGTA-
CAGCCCCATCTC and REV: CTTGACCAGAGATCCGAGGG, Pax3 FW:
CAAACCCAAGCAGGTGACAA and REV: TTTACTCCTCAGGATGCGGC,
Oct4 promoter (Tead2 BS) FW: GCAGAAGGTCAGGTCCACTC and REV:
AGAACCCCACGACATCACTC, Oct4 promoter (β-catenin BS) FW:
TGGGGGCAGAGAAGATGGTTG and REV: AAGGCAGCGACTTGGAAGCC,
p53 upstream element FW: TGGGGCTAGAAGTACCTCCC and REV:
CGTGAGGGACACCATTTCCA, Fbxw7 upstream element FW: TTA-
GACTGGGATGGGAGGGG and REV: GGGTTTGTGGGGGAAGAGAG, Klf3
upstream element FW: TGGCGATTGTTGCTTGTTGG and REV:
TCCCTCTCCTCTCTTCAGGC, Tead1 upstream element FW:
CCTTTTGCAGTGTTCCAGCC and REV: AGGGAAGGCTACTGAGAGGG,
Rassf1A promoter FW: GTACAACACGCAATCCGTCA and REV:
GAAGTCTCCACAGAGGTCGC, β-actin promoter FW: AAATGCTG-
CACTGTGCGGCG and REV: AGGCAACTTTCGGAACGGCG.
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Immunofluorescence. Cells plated onto gelatin-coated glass coverslips (Fisher)
were fixed in 4% Paraformaldehyde solution (in PBS), permeabilised with 0.2%
Triton X solution (in PBS) and blocked in 0.2% fish skin gelatin (in PBS). The cells
were next incubated in primary antibody at 4 °C overnight and then washed three
times with PBS before secondary antibody incubation for 1 h at RT. Cells were
mounted onto microscope slides using Prolong Gold antifade reagent with DAPI
(Life Technologies) and confocal microscopy was carried out using Zeiss LSM710
microscope with the Zeiss ZEN software. The following primary (dilution 1:100)
and secondary (dilution 1:500) antibodies were used: Nanog (ab80892), Oct4
(ab19857), Sox2 (MAB4423), pS127 YAP (Cell Signaling; 4911), p73 (Imgenex;
img-246), ki67 (AB9260), YAP (sc-15404 and sc-101199), Nestin (sc-20978), Alexa
fluor goat anti-rabbit and anti-mouse (Invitrogen).
DNA constructs and RNA interference experiments. For siRNA-mediated
silencing and transient plasmid expression in ESCs, Lipofectamine 2000 (Invitro-
gen) was used in reverse transfections according to manufacturer’s instructions.
For plasmid expression in MEFs, electroporation was performed using the
Nucleofector II device (Lonza). Infections were performed with the use of
HEK293T cells. shRNA sequences were cloned into the pLKO.1 puro lentiviral
vector to generate stable ESC lines. Stable MEF cell lines were generated after
infection with a pBabe puro retroviral vector. The following oligonucleotides were
used for siRNA-mediated silencing: non-targeting (NT): 5′-TAAGGTATGAA-
GAGATAC-3′, Rassf1a #1 5′- CAGAACTCATTGAACTACGCGAGCT-3′, Rassf1a
#2 5′-TGCGACCTCTGTGGAGACTTCATCT-3′. siRNAs to Tead2, Yap, Catnb,
Trp73, Lats1, Tcf3, Tcf4, Gata1 and Tead1 were purchased from Qiagen. The
following oligonucleotides were used for shRNA-mediated silencing: GFP
5′–CCGG-GCTGACCCTGAAGTTCATCTT-CTCGAG-AAGATGAACTT-
CAGGGTCAGC-TTTTTG-3′ Rassf1a 5′-CCGG-CTGCAAGTTCACCTGC-
CATTA-CTCGAG-TAATGGCAGGTGAACTTGCAG-TTTTTG-3′, Tead2 5′-
CCGG-CCTCTTAGAAAGGAACCGGAA-CTCGAG-
TTCCGGTTCCTTTCTAAGAGG-TTTTTG-3′. MEFs transfected with pBabe
puro were cultured in the presence of 1–2 μg/mL of puromycin for 2–3 days. ESCs
transfected with pLKO.1 puro were cultured in the presence of 1.75 μg/mL of
puromycin for 2 days. pcDNA3 GATA1 was a gift from Licio Collavin & Giannino
Del Sal (Addgene plasmid # 85693).
Proximity ligation assay (PLA). ESCs were transfected with the indicated con-
structs and 24 h post-transfection they were transferred into gelatinised (0.1%
gelatin) 16-well chamber slides (Fisher) and cultured for a further 24 h. Cells were
subsequently fixed and assayed using the PLA kit (Duolink) according to the
manufacturer instructions. Briefly, after applying primary antibodies, cells were (1)
Incubated with plus and minus probes for 1 h, (2) DNA strands were subjected to
ligase treatment for 30 min, (3) DNA was amplified for 100 min with the addition
of polymerase and (4) slides were mounted and PLA dots were detected via con-
focal microscopy (Zeiss LSM710), using the Zeiss ZEN software. The following
primary antibodies were used: p73 (Imgenex; img-246; dilution 1:100) and pS127
YAP (Cell Signaling; 4911; dilution 1:100).
Reprogramming of MEFs into iPS cells. Reprogramming of MEFs was performed
by inducing expression of defined transcription factors (Sox2, Klf4, Oct4, c-Myc,
referred to as SKOM)54. For transgene expression the piggyBac transposition
system55 was used. SKOM transposon was used together with PBase transposase.
Immediately after the transfection, MEFs were seeded on feeder layer-containing
dishes and left in culture for approximately 11 days before they were stained for
Nanog and alkaline phosphatase expression using the Vector Black Alkaline
Phosphatase Substrate Kit II.
Differentiation assays. For LIF withdrawal assays, ESCs and iPSCs originally
cultured in complete ESC medium (ESC medium supplemented with LIF) were
subject to LIF-free culture for 4–20 days and assessed periodically for morpholo-
gical changes, expression of stem cell markers and differentiation capacity via
microscopy, western blotting, qRT-PCR and differentiation assays. For EB for-
mation, iPSCs were trypsinised and replated to 90 mm non-gelatinised Petri dishes
(Sterilin) at a concentration of 4 × 105 cells/dish in a total volume of 20 ml ESC
medium in the absence of LIF. The cells were cultured for 8 days, observing
periodically to ensure that the medium did not become exhausted. Proliferation of
stem cells under these conditions resulted in the formation of large aggregates that
comprise EBs, the latter being macroscopic at approximately day 4–5 of culture.
Differentiation towards neural progenitors was carried out as follows: EBs were
allowed to be formed and then cultured in neural differentiation medium
consisting of Neurobasal medium (Gibco 21103) supplemented with B27 (Gibco
17504), N2 (Invitrogen 17502-048) and RA (100 nM; Sigma R2625) for 3–4 days.
Subsequently, EBs were stained for neural progenitor markers.
Differentiation towards DCs was carried out as previously described56. Briefly,
after EB formation, all EBs were transferred to a 50 ml Falcon tube and allowed for
10–20 min to sediment under unit gravity. Following that, the medium was
replaced with fresh ESC medium (LIF-free) prior to transferring to new Petri
dishes. Six days later, EBs were harvested by sedimentation and washed gently
twice in complete DMEM medium. The EBs were subsequently seeded at low
density (approximately 10–30 EBs per plate) into non-gelatinised 10-cm tissue
culture plates in LIF-free ESC medium supplemented with 2% GM–CSF-
conditioned medium (Life Technologies) and 1000 U/mL of recombinant IL-3
(rIL-3;R & D systems). Following overnight culture, a proportion of the EBs
attached to the dishes and began to develop colonies in a radial fashion which
continued to grow until they eventually formed a stromal layer. DCs were observed
around the perimeter of the colonies approximately 4 days later and continued to
expand.
Flow cytometry. Fixation and immunostaining of cells were done according to the
Cell Signaling Technology protocol for Flow Cytometry. 106 cells/condition were
analysed on a BD FACSCalibur flow cytometer. A cd54 (I-CAM) antibody (Novus
Biologicals; NBP1-72025; 1:100 dilution) was used.
Chromatin immunoprecipitation. ChIP from ESCs was performed according to
the ChIP-IT High Sensitivity kit (Active Motif). Chromatin sonication was
achieved with the use of Bioruptor Plus, Diagenode, at low amplitude, pulse for 30 s
on and 30 s off for 20 min in ChIP buffer. 1/20 of the chromatin preparation was
extracted to generate the Input. 15–30 μg of chromatin and 4 μg of antibody per
ChIP reaction were used. Binding to promoter regions was assessed via qPCR. YAP
(clone 63.7; sc-101199), TEF-4 (sc-67115), β-catenin (sc-7199), GATA-1 (sc-
13053), H3K4Me3 (ab8580), H3 (Cell Signalling; 14269 S), H3K27Me3 (Cell Sig-
nalling; 9733 S) and IgG (Cell Signalling; 2729 S) antibodies were used for the
immunoprecipitations.
Embryo collection and culture. Animals were maintained in the Gurdon Institute
Animal Facility at 12:12 light cycle and free access to food and water was constantly
ensured. Experiments were conducted in accordance with Home Office regulations.
For embryo collection, 4–6 weeks old mice belonging to the C57Bl6 and CBA
strains (F1 generation) were superovulated with 10 IU of pregnant mare serum
gonadotropin (PMSG; Intervet) and 10 IU human chorionic gonadotropin
(Intervet) and mated with F1 (C57Bl6 × CBA) males 48 h post treatment. Dissec-
tion of embryos out of the oviducts was performed into M2 medium and for zygote
recovery cumulus cells were subjected to hyaluronidase treatment (1 mg/mL).
Cultures of embryos were maintained in drops of KSOM media (Millipore) under
paraffin oil in 5% CO2 at 37 °C.
Embryo microinjection and analysis. Embryo microinjection was carried out on a
Leica DM IRB microscope with attached Leica micromanipulators. Injections were
carried out in embryos maintained in M2 medium under paraffin oil on a
depression slide via air pressure with an Eppendorf Femtojet microinjector. Use of
negative capacitance ensured membrane penetration.
For immunofluorescence experiments, embryos were fixed in 4% PFA for 20
min and washed 2 × 5min in PBS-T (PBS containing 0.1% Tween).They were
subsequently permeabilized with 0.5% Triton X-100 in PBS for 20 min and washed
3 × 5 min in PBS-T. The following primary antibodies were used for overnight
incubation following dilution in 3% BSA (Sigma):Oct4 (Santa Cruz sc-5279; 1:200),
Nanog (Abcam ab80892; 1:200) and Yap (Santa Cruz sc-15407; 1:400). Embryos
were washed 3 × 5min in PBS-T before secondary antibodies (Invitrogen,
AlexaFluor) and DAPI (Invitrogen) were applied for 1 h at a dilution of 1:400 and
1:1000 respectively in 3% BSA (Sigma). Embryos were placed overnight into M2
media following 3 × 5min washes in PBS-T and imaged on glass-bottom dishes to
prevent flattening. Confocal images were acquired on a Leica SP5 microscope with
Fig. 5 Premature activation of RASSF1A impairs embryogenesis via p73. a Indicated gene expression levels in published GEO data sets GDS3599 and
GDS2156. b Temporal expression of Oct4 and Rassf1A mRNA in the pre-implantation embryo (% of maximum expression) from published GEO data sets
GDS752 (black colour) and GDS814 (red colour). c Nuclear localisation of YAP during early stages of pre-implantation development. d Nanog
immunofluorescence and e representative images of embryos microinjected with either control (zsCtrl) or RASSF1A-expressing (zsR1A) vectors stained for
stem cell marker expression. Bar graph showing total OCT4 protein levels across all embryos in zsR1A versus zsCtrl. f 'Kill curve' to determine lethal
RASSF1A concentration in pre-implantation embryos. The graph expresses percentage (%) of blastocyst-forming embryos at the indicated RASSF1A
concentration. g Viability of embryos in response to RASSF1A expression and/or sip73 microinjection, n= 15. BF bright field channel. Scale bars: 10–50 μm.
*P< 0.05, of Student’s t-test. Error bars indicate s.e.m
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Fig. 6 RASSF1A is a barrier to somatic cell reprogramming and iPS cell self-renewal. a Experimental scheme for iPSC generation from MEFs. b Top: example
images of Nanog/alkaline phosphatase (AP)-positive round iPSC colonies and quantification of reprogramming efficiency in the respective conditions. c
qPCR in MEFs and iPSC for core stem cell marker expression. d Proteomics analysis for the YAP interactome in iPSC from indicated conditions. See also
Supplementary Data 5. e Representative iPSC colonies from indicated conditions subject to LIF withdrawal assay. Quantification is provided in
Supplementary Fig 8h. f Neural differentiation of Rassf1A+/+ and −/− iPSC in N2B27 medium and retinoic acid (RA). Differentiation capacity of iPSC into
neural progenitors is assessed via Nestin and Pax3 expression g Model. Scale bars: 25–50 μm. *P < 0.05, **P< 0.01 and***P< 0.001, respectively, of
Student’s t-test. Error bars indicate s.e.m. Data shown are representative of at least three independent experiments
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a Z-resolution of 4 µm. Signal intensity differences were layer normalised using
IMARIS.
zsCtrl and zsRASSF1A were cloned into pRN3p for in vitro transcription67.
mRNA was produced using the mMESSAGE mMACHINE Kit (Life Technologies).
RNA was extracted from embryos with the Arcturus PicoPure RNA Isolation Kit.
qPCR was performed using SYBR Green in a StepOne Plus Real-time PCR
machine (Applied Biosystems).
ChIPseq and RNAseq data processing. ChIP seq tags were pre-processed by
trimGalore (http://www.bioinformatics.babraham.ac.uk/projects/trim_galore/) to
remove sequencing adaptors and low quality regions. Trimmed read alignment was
performed against mouse reference genome (mouse genome version mm9) with
Bowtie aligner using default parameters. We used Picard tools to remove
sequencing PCR duplicates. The ChIP seq peaks were identified independently by
MACS2 (http://liulab.dfci.harvard.edu/MACS/) and PePr68 packages. The peaks
called by both methods were subjected to further analyses. Both packages were run
in narrow peaks detection mode and FDR threshold was 0.01. RNA seq reads were
pre-processed to remove sequencing adaptors and low quality regions as ChIP seq
data. The resulting reads were aligned against reference genome by STAR aligner69.
RNA seq raw read counts were calculated with htseq-count script using RefSeq
gene annotation for mouse genome. The differential gene expression was called
with DeSEQ2 R package. For integrative analysis of RNA seq and ChIP seq data,
binding and expression data integration and analysis was performed by BETA
software package in “plus” mode (http://cistrome.org/BETA/). The average profiles
of ChIP enrichment signal within and near differentially expressed genes, as well as
relative enrichment of ChIP regions in important genomic features were computed
with CEAS package70.
Additionally, FASTQC (http://www.bioinformatics.babraham.ac.uk) quality
control was performed. FASTQC provides summary statistics and quality control
checks on raw sequence data. Total sequences and sequence quality scores were
considered as the main criteria, with default thresholds for rejection; when residual
adaptor sequences were detected they were clipped using Trimmomatic (http://
www.usadellab.org). Mapping and alignment were done using Bowtie2 and
TopHat2 (http://tophat.cbcb.umd.edu/). TopHat2 is a fast splice junction mapper
for RNA sequencing reads; specifically, it aligns the reads to mammalian-sized
genomes using the short read aligner Bowtie2, and then analyses the mapping
results to identify splice junctions between exons. Paired pre- and post-treatment
samples for each patient were processed using two different methods; Cuffdiff
(http://cufflinks.cbcb.umd.edu) for transcript assembly and quantification of gene
expression changes. Ensemble gene IDs were used as reference. Genes were ranked
by their differential gene expression as estimated by Cuffdiff; rank product was
used to merge samples from different conditions and to call the significantly up-
regulated and down-regulated genes; The Bioconductor EdgeR package (http://
www.bioconductor.org/packages/release/bioc/html/edgeR.html).
Statistical analysis. For all experiments reported in this manuscript, at least three
biological replicates were used and statistical significance was determined by Stu-
dent’s t-test. To ensure randomization, for in vivo experiments animals were
assigned randomly to either the experimental or control group. Additionally, the
experiments were blinded to ensure unbiased interpretation of results.
Data availability statement. Published GEO data sets are analysed in Figs. 1, 5
and Supplementary Fig. 7. These have the following accession codes: In Fig. 1—
GSE54186, GSE3749, GDS2672; in Fig. 5—GDS3599, GDS2156, GDS752, GDS814
and GDS3599, GDS1824, GSE54186, GDS2156 were also discussed in Supple-
mentary Fig. 7. The authors declare that all data supporting the findings of this
study are available within the article and its supplementary information files or
from the corresponding author upon reasonable request.
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